fatih kalem indir / Fatih Kalem - Загрузить

Fatih Kalem Indir

fatih kalem indir

ID: covidwho-2091802

Реферат
BACKGROUND: Studies regarding effectiveness of anakinra and tocilizumab treatments in coronavirus disease 2019 (COVID-19) have contradictory results. Furthermore, there is scarce comparative data regarding superiority of any agent. To further elucidate any superiority between these two agents, we retrospectively investigated and compared outcomes in hospitalized COVID-19 patients of our inpatient cohort who received anakinra or tocilizumab. METHODS: This study was designed as a single-center, retrospective, cross-sectional cohort study. Hospitalized patients with confirmed diagnosis of COVID-19 who had Brescia-COVID respiratory severity scale score ≥3 and hyperinflammation (defined as elevation of C reactive protein ≥50 g/L or ferritin ≥700 ng/mL) and received anakinra or tocilizumab in addition to standard care were enrolled in the study. Length of hospital stay after initiation of antiinflammatory treatment, need for mechanical ventilation, need for intensive care unit admission, mortality were set as primary outcomes and compared between tocilizumab and anakinra recipients after propensity score matching. RESULTS: One hundred and six patients were placed in each group after propensity score matching. In the anakinra group, relative risk reduction for intensive care unit admission was 50% when compared to the tocilizumab group and the number needed to treat to avert an intensive care unit admission was 3 (95% CI, 2-5). In terms of mortality, a 52% relative risk reduction was observed with anakinra treatment and the number needed to treat to avert an intensive care unit admission was 8 (95% CI, 4-50). Significantly more patients were observed to receive glucocorticoids in the anakinra group. DISCUSSION: Anakinra administration in severe COVID-19 patients was significantly associated with better survival and greater clinical improvement compared to the tocilizumab administration in our study. Increased rate of glucocorticoid use in the anakinra group might have contributed to better outcomes.

Тема - темы

COVID-19 Drug Treatment , Interleukin 1 Receptor Antagonist Protein , Humans , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Retrospective Studies , Cross-Sectional Studies , Cohort Studies

4.

Modified Proline Metabolism and Prolidase Enzyme in COVID-19.

Ergin Tuncay, Merve; Neselioglu, Salim; Asfuroglu Kalkan, Emra; Inan, Osman; Sena Akkus, Meryem; Ates, Ihsan; Erel, Ozcan.

Lab Med ; 53(5): 453-458, 2022 Sep 01.

Статья в английский ID: covidwho-2099174

Реферат
Background: The aim of the study is to assess the effect of chronic lung disease on mortality in patients hospitalized with the diagnosis of prevariant COVID-19 Pneumonia compared to patients without chronic lung disease. Research design and methods: A cohort of 1,549 patients admitted to the pandemic clinic with a COVID-19 Pneumonia diagnosis was analyzed. Group 1 and Group 2 were compared in terms of the treatment they received, admission to intensive care, mortality and follow-up parameters. Results: The patient group with COVID-19 and lung disease consisted of 231 participants (14.91%) (Group 1). The patient group with COVID-19 but without lung disease had 1,318 participants (85.19%). Group 1 cases were found to receive more oxygen therapy and mechanical ventilation than Group 2 cases (p ≤ 0.001), Following univariate and multiple logistic regression analyses, it was determined that patients with chronic lung disease had a 25.76% higher mortality risk [OR: 25.763, 95% CI (Lower-Upper) (2.445-271.465), p = 0.007]. Conclusion: It was found that chronic lung disease contributed significantly to mortality in this study. Among chronic lung diseases, Chronic Obstructive Pulmonary Disease (COPD), lung cancer and interstitial lung diseases (ILDs) were shown to be more effective than other chronic lung diseases in patients with prevariant COVID-19 population.

3.

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.

Küçüksahin, Orhan; Erden, Abdulsamet; Karakas, Özlem; Güven, Serdar Can; Armagan, Berkan; Sahiner, Enes Seyda; Inan, Osman; Kurtipek, Ali Can; Gemcioglu, Emin; Karaahmetoglu, Selma; Turan, Sema; Izdes, Seval; Erdem, Deniz; Aypak, Adalet; Ayhan, Müge; Akinci, Esragül; Bodur, Hürrem; Güner, Rahmet; Omma, Ahmet; Ates, Ihsan.

Turk J Med Sci ; 52(5): 1486-1494, 2022 Oct.

Статья в английский ID: covidwho-2134570

Реферат
Protective neutralizing antibody titers reduce in time after COVID-19 vaccinations, as in individuals who have had COVID-19. This study aimed to evaluate the safety and immunogenicity of CoronaVac and TURKOVAC vaccines used as a booster dose after CoronaVac primary vaccination. This double-blind, randomized, controlled, phase II, multicenter study included healthy male and female adults (18-60 years) who were vaccinated with two doses of CoronaVac vaccine and did not exceed the duration of at least 90 days and a maximum of 270 days from the second dose of vaccination. Among 236 eligible volunteers, 222 were recruited for randomization between July 12, 2021 and September 10, 2021; 108 and 114 were randomized to the TURKOVAC and CoronaVac arms, respectively. The primary endpoint was adverse events (AEs) (ClinicalTrials.gov; Identifier: NCT04979949). On day 28, at the neutralizing antibody threshold of 1/6, the positivity rate reached 100% from 46.2% to 98.2% from 52.6% in the TURKOVAC and CoronaVac arms, respectively, against the Wuhan variant and the positivity rate reached 80.6% from 8.7% in the TURKOVAC arm vs. 71.9% from 14.0% in the CoronaVac arm against the Delta variant. IgG spike antibody positivity rate increased from 57.3% to 98.1% and from 57.9% to 97.4% in the TURKOVAC and CoronaVac arms, respectively. The TURKOVAC and CoronaVac arms were comparable regarding the frequency of overall AEs. Both vaccines administered as booster yielded higher antibody titers with acceptable safety profiles.
What is the context? The timing of the primary and booster doses for each vaccine differs.We aimed to evaluate the safety and immunogenicity of CoronaVac and TURKOVAC vaccines used as homologous booster dose after CoronaVac primary vaccination.What is new? The neutralizing antibody titers against the Wuhan variant decreased below 1/6- the seropositivity threshold value- in more than 55% of the participants 4 months after administration of two doses of CoronaVac vaccine.Immunogenicity was re-stimulated and the neutralizing antibody titers increased rapidly and markedly with the administration of the CoronaVac or TURKOVAC as a booster dose 4 months after the second dose.While the increase in neutralizing antibodies against the Wuhan variant was similar with both CoronaVac and TURKOVAC, more antibodies developed against the Delta variant with TURKOVAC.What is the impact? With the Hybrid COV-RAPEL TR study, after the primary vaccination consisting of two doses of inactivated vaccine, antibody titers decreased in the long term; however, higher antibody titers are achieved than the primary vaccination after the booster dose administered after 46 month interval.Booster application with TURKOVAC provides antibodies at least as much as the CoronaVac booster dose, with an acceptable safety profile.

2.

Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients.

Kilic, Hatice; Arguder, Emine; Karalezli, Aysegul; Unsal, Ebru; Guner, Rahmet; Kayaslan, Bircan; Hasanoglu, Imran; Ates, Ihsan; Civak, Musa; Akpinar, Esmehan; Parlak, Ebru; Sadi, Filiz; Kocaman, Yasin; Günay, Sibel; Metan, Esra; Er, Mukremin; Dalkiran, Aynil; Hezer, Habibe; Ergüden, Hülya; Hancioglu, Zeynep; Kalem, Ayse; Eser, Fatma; Aypak, Adalet; Akinci, Esragül; Karahmetoglu, Selma; Gemcioglu, Emin; Kalkan, Emra; Inan, Osman; Yilmaz, Abdulrezzak; Güler, Bagdagul; Çopuroglu, Esra; Turan, Isil; Gökmen, Derya; Hayme, Serhat; Surel, Aziz Ahmet.

Front Med (Lausanne) ; 9: 957598, 2022.

Статья в английский

nest...

23903 23904 23905 23906 23907

batman iftar saati 2021 viranşehir kaç kilometre seferberlik ne demek namaz nasıl kılınır ve hangi dualar okunur özel jimer anlamlı bayram mesajı maxoak 50.000 mah powerbank cin tırnağı nedir